Phase 1 AZD9550 AZD6234 Hepatic Impairment Safety Study
Summary
AstraZeneca registered Phase 1 trial NCT07546760 investigating the safety and tolerability of AZD9550 and AZD6234 in participants with hepatic impairment compared to participants with normal hepatic function. The single-arm open-label study will enroll participants with varying degrees of hepatic function to assess how hepatic impairment affects drug exposure. This registry record was posted to ClinicalTrials.gov on April 23, 2026.
“The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This ClinicalTrials.gov registry entry records the initiation of a Phase 1 clinical trial sponsored by AstraZeneca. The study will evaluate AZD9550 and AZD6234 in participants with hepatic impairment and participants with normal hepatic function. Participants receiving the interventions will be monitored for safety and tolerability across different hepatic function strata. Clinical investigators and sponsors conducting hepatic impairment studies should be aware that this registry reflects current FDA and ICH guidance on assessing pharmacokinetics in special populations.
Pharmaceutical companies developing drugs that may be used in patients with liver disease should consider this trial as a benchmark for hepatic impairment study design. Contract research organizations and clinical investigators should note the specific conditions (hepatic impairment) and interventions (AZD6234, AZD9550) as relevant for patient recruitment and site selection.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Phase 1 NCT07546760 Kind: PHASE1 Apr 23, 2026
Abstract
The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
Conditions: Hepatic Impairment
Interventions: AZD6234, AZD9550
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.